Related Experiment Video
Updated: Oct 27, 2025
Studying Pre-formed Fibril Induced α-Synuclein Accumulation in Primary Embryonic Mouse Midbrain Dopamine Neurons
Published on: August 16, 2020
SCD Inhibition Protects from α-Synuclein-Induced Neurotoxicity But Is Toxic to Early Neuron Cultures
Justin W Nicholatos1,2, Joost Groot3, Shekhar Dhokai4
1Neurodegeneration Research Unit, Biogen, Cambridge, MA 02142.
Abstract:
Here, we report the independent discovery and validation of stearoyl-CoA desaturase (SCD) as a modulator of α-synuclein (αSyn)-induced pathology and toxicity in cell-based Parkinson's disease (PD) models. We identified SCD as top altered gene from transcriptional profiling in primary neurons exogenously expressing αSyn with the amplified familial PD mutation 3K. Thus, we sought to further explore SCD as a therapeutic target in neurodegeneration. We report that SCD inhibitors are toxic to early human and rat neuron cultures while displaying minimal toxicity to late cultures. The fatty acid product of SCD, oleic acid (OLA), fully rescues this toxicity in early cultures, suggesting on-target toxicity. Furthermore, SCD inhibition rescues αSyn 3K-induced toxicity in late primary neurons. We also confirm that SCD inhibitors reduce formation of αSyn accumulations, while OLA increases these accumulations in an αSyn 3K neuroblastoma model. However, we identify a caveat with this model where αSyn 3K levels can be suppressed by high SCD inhibitor concentrations, obscuring true effect size. Further, we show that both SCD1 or SCD5 knock-down reduce αSyn 3K accumulations and toxicity, making both a putative drug target. Overall, we confirm key findings of published data on SCD inhibition and its benefits in αSyn accumulation and stress models. The differential neurotoxicity induced by SCD inhibition based on neuron culture age must be accounted for when researching SCD in neuron models and has potential clinical implications. Lastly, our gene profiling studies also revealed novel putative genes connected to αSyn neurotoxicity that are worth further study.
Insights
Stearoyl-CoA desaturase (SCD) modulates Parkinson's disease pathology by affecting alpha-synuclein (αSyn) toxicity. SCD inhibition shows promise for neurodegeneration, but age-dependent toxicity in neurons requires careful consideration.
Area of Science:
- Neuroscience
- Molecular Biology
- Biochemistry
Background:
- Alpha-synuclein (αSyn) aggregation is central to Parkinson's disease (PD) pathology.
- Stearoyl-CoA desaturase (SCD) is a key enzyme in fatty acid metabolism, implicated in cellular stress.
- Identifying novel therapeutic targets for neurodegenerative diseases like PD is crucial.
Purpose of the Study:
- To investigate stearoyl-CoA desaturase (SCD) as a potential therapeutic target for Parkinson's disease (PD).
- To evaluate the role of SCD in modulating alpha-synuclein (αSyn)-induced pathology and toxicity in neuronal models.
- To assess the therapeutic potential and safety of SCD inhibitors in neurodegeneration.
Main Methods:
- Transcriptional profiling of primary neurons expressing αSyn with familial PD mutation (3K).
- Treatment of early and late-stage human and rat neuron cultures with SCD inhibitors and oleic acid (OLA).
- Assessment of αSyn accumulation and toxicity in neuroblastoma models with SCD inhibition and OLA treatment.
- Knock-down studies of SCD1 and SCD5 in neuronal models.
Main Results:
- SCD was identified as a top-altered gene in neurons expressing αSyn (3K).
- SCD inhibitors exhibited age-dependent toxicity in neuron cultures; OLA rescued toxicity in early cultures.
- SCD inhibition reduced αSyn (3K) toxicity and accumulation in late-stage neurons.
- SCD1 and SCD5 knock-down decreased αSyn (3K) accumulation and toxicity.
Conclusions:
- SCD is a significant modulator of αSyn pathology and toxicity in PD models.
- SCD inhibition demonstrates therapeutic potential for neurodegeneration, but age-dependent neurotoxicity must be addressed.
- SCD1 and SCD5 represent putative drug targets for Parkinson's disease.
- Further research into novel genes identified in gene profiling may uncover new therapeutic avenues.
